Compare MRAM & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | AVXL |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.8M | 289.1M |
| IPO Year | 2016 | 2013 |
| Metric | MRAM | AVXL |
|---|---|---|
| Price | $13.21 | $3.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $14.00 | ★ $22.00 |
| AVG Volume (30 Days) | 457.9K | ★ 1.0M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,417,000.00 | N/A |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $7.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $5.34 | $2.61 |
| 52 Week High | $17.24 | $13.99 |
| Indicator | MRAM | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 63.72 | 44.61 |
| Support Level | $8.22 | $2.93 |
| Resistance Level | $15.93 | $3.76 |
| Average True Range (ATR) | 0.80 | 0.20 |
| MACD | 0.16 | 0.04 |
| Stochastic Oscillator | 69.04 | 43.53 |
Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.